{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-108726","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.701234+00:00","generated_at":"2026-05-23T00:51:32.021200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom Q1 net revenue $28.5M, net loss $94.3M; cuts costs, exec changes, targets 2026 profit","bullets":["Net revenue $28.5M (up from $1.9M YoY); net loss $94.3M ($77.1M non-GAAP adjusted).","Over 390k VOQUEZNA prescriptions filled; ~127k in Q1, up ~8% sequentially despite seasonal headwinds.","Cost reduction: cut 2025 opex by $60-70M, reduce headcount ~6%, pause EoE trial, target Q4 spend <$55M.","CEO restructuring: new SVP Sales from Intra-Cellular; COO, CCO, CFO exit; Ted Schroeder on Board.","Citizen Petition filed Dec 2024 for 10-year NCE exclusivity; FDA response due within 180 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-108726","json":"https://secwatch.observer/filing/0001193125-25-108726.json","markdown":"https://secwatch.observer/filing/0001193125-25-108726.md","text":"https://secwatch.observer/filing/0001193125-25-108726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525108726/0001193125-25-108726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525108726/d847727d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:51:32.021200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}